FIX started coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a report released on Monday, The Fly reports. The firm issued a reduce rating and a $64.00 price target on the stock.

Other research analysts have also issued research reports about the stock. BidaskClub lowered shares of Aerie Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, November 10th. Cowen boosted their price objective on shares of Aerie Pharmaceuticals from $100.00 to $105.00 and gave the stock a buy rating in a research note on Thursday, August 9th. Oppenheimer initiated coverage on shares of Aerie Pharmaceuticals in a research note on Monday. They set a buy rating and a $64.00 price objective for the company. ValuEngine upgraded shares of Aerie Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, August 14th. Finally, Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a sell rating to a buy rating and set a $60.00 price objective for the company in a research note on Wednesday, October 10th. Two investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $79.25.

Shares of AERI opened at $41.82 on Monday. Aerie Pharmaceuticals has a 1-year low of $40.50 and a 1-year high of $74.75. The stock has a market cap of $2.03 billion, a P/E ratio of -12.41 and a beta of 0.99.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, November 6th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.40). The firm had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.63 million. On average, equities analysts forecast that Aerie Pharmaceuticals will post -5.48 earnings per share for the current fiscal year.

In other Aerie Pharmaceuticals news, CFO Richard J. Rubino sold 34,512 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $60.17, for a total transaction of $2,076,587.04. Following the sale, the chief financial officer now owns 383,738 shares of the company’s stock, valued at approximately $23,089,515.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Casey C. Kopczynski sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $53.87, for a total transaction of $592,570.00. Following the sale, the insider now directly owns 139,768 shares in the company, valued at approximately $7,529,302.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 324,117 shares of company stock worth $19,459,226. 10.53% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. UBS Group AG boosted its holdings in shares of Aerie Pharmaceuticals by 142.3% in the 1st quarter. UBS Group AG now owns 9,409 shares of the company’s stock valued at $511,000 after acquiring an additional 5,526 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Aerie Pharmaceuticals by 8.3% in the 1st quarter. Royal Bank of Canada now owns 32,875 shares of the company’s stock valued at $1,784,000 after acquiring an additional 2,511 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Aerie Pharmaceuticals in the 1st quarter valued at $258,000. Amalgamated Bank boosted its holdings in shares of Aerie Pharmaceuticals by 20.0% in the 2nd quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock valued at $368,000 after acquiring an additional 906 shares during the last quarter. Finally, Columbus Circle Investors boosted its holdings in shares of Aerie Pharmaceuticals by 22.7% in the 2nd quarter. Columbus Circle Investors now owns 774,180 shares of the company’s stock valued at $52,296,000 after acquiring an additional 143,133 shares during the last quarter. 96.86% of the stock is currently owned by institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Article: Analyzing a company’s cash flow statement

The Fly

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.